Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Pixium Vision in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$75.00.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Pixium Vision. This N/A consensus rating has held steady for over two years.
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh. Pixium Vision SA was founded in 2011 and is based in Paris, France.
Read More
